Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says

Sep 12 2005

• By Andrew Kasper

Related Content

Genentech/OSI's Tarceva Will Be Detailed Alongside Herceptin

Nov 19 2004

Genentech/OSI Tarceva Pancreatic Cancer sNDA Planned For First Half 2005

Feb 07 2005

Abbott Xinlay Lack Of Efficacy, CV Safety Will Be Likely Focus Of Advisory Cmte. Review

Sep 12 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window